Fed. Circ. Rules Use Code Off Limits In Prandin IP Case

Law360, New York (April 15, 2010, 6:04 PM EDT) -- A federal appeals court has thrown out an order directing Novo Nordisk A/S to change back its patent use code for the diabetes drug Prandin, saying generic-drug company Caraco Pharmaceutical Laboratories Ltd. did not have a right to challenge the code's change.

The U.S. Court of Appeals for the Federal Circuit said Wednesday that Caraco did not have a statutory basis to request the order, which would have changed the use code back to what it originally was in the U.S. Food and Drug Administration's Orange...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.